KOL Perspectives on Recent Advancements in Hematology: How CAR-T, Bispecific Antibodies, and MRD-Driven Care Are Reshaping Clinical Practice
A hematology KOL perception study exploring how 40 Key Opinion Leaders across the United States and Europe view CAR-T therapies, bispecific antibodies in hematology, gene editing in hematology, MRD-guided treatment strategies, and future trends in hematology treatment innovations and expert insights.
Introduction
KOL Perception of Recent Advancements in Hematology
Hematology is entering one of the most transformative periods in its history. Innovations such as CAR-T therapies, bispecific antibodies in hematology, gene-editing technologies, and measurable residual disease (MRD)-guided treatment strategies are redefining how clinicians approach blood cancers and rare hematologic disorders.
Yet scientific breakthroughs alone do not determine future standards of care. Understanding how leading hematologists interpret emerging evidence provides an early signal of which innovations are most likely to influence clinical practice, investment priorities, and patient outcomes.
To explore these perspectives, a hematology primary research study among US and European KOLs was conducted among 40 Key Opinion Leaders (KOLs) across the United States (n=20) and Europe (n=20). The findings reveal a healthcare community enthusiastic about therapeutic innovation while remaining focused on persistent challenges surrounding access, reimbursement, and long-term durability of response. These findings offer valuable hematology market intelligence, providing deeper hematology expert insights into how the field may evolve over the coming years.
Study Objective
To understand KOL perception of recent advancements in hematology and assess how experts view CAR-T therapies, bispecific antibodies, gene editing, MRD-guided treatment strategies, and emerging hematology treatment innovations.
This hematology KOL perception study provides evidence-based hematology expert insights for pharmaceutical companies, medical affairs teams, healthcare providers, and investors.
Respondent Profile
This hematology primary research study among US and European KOLs delivers directional intelligence on clinical adoption, innovation priorities, CAR-T adoption barriers, and future standards of care.
KOL Perception of Recent Advancements in Hematology
Summary Findings
Cellular therapies are viewed as the most transformative innovation.
- US Response: CAR-T: 65%; Bispecifics: 20%; Gene Therapy: 15%.
- EU Response: CAR-T: 55%; Bispecifics: 25%; Gene Therapy: 20%.
- CAR-T selected by 60% overall.
Strong positive perception of efficacy and treatment accessibility.
- US Response: Very High: 70%; Moderate: 25%; Low: 5%.
- EU Response: Very High: 60%; Moderate: 35%; Low: 5%.
- 65% rated impact as "Very High".
Access and logistics remain key challenges.
- US Response: Access/Referral: 50%; Cost: 30%; Toxicity: 20%.
- EU Response: Access/Referral: 40%; Cost: 20%; Reimbursement: 40%.
- Access-related issues cited by 45% overall.
High confidence in long-term potential.
- US Response: Very Optimistic: 75%; Somewhat: 20%; Neutral: 5%.
- EU Response: Very Optimistic: 65%; Somewhat: 30%; Neutral: 5%.
- 70% very optimistic overall.
Multiple myeloma remains the leading area for innovation.
- US Response: MM: 45%; AML: 30%; Sickle Cell Disease: 25%.
- EU Response: MM: 40%; AML: 25%; Sickle Cell Disease: 35%.
- Multiple Myeloma selected by 43% overall.
MRD-guided decision-making expected to become standard.
- US Response: Very Likely: 80%; Somewhat: 15%; Unlikely: 5%.
- EU Response: Very Likely: 70%; Somewhat: 25%; Unlikely: 5%.
- 75% believe adoption is very likely.
Q7
Most Important Unmet Need in Hematology Today
Durable responses and equitable patient access remain priorities across hematology practice.
Unmet Need Insight
US Response: Durable Remission: 40%; Access: 35%; Toxicity Reduction: 25%. EU Response: Access: 45%; Durable Remission: 35%; Toxicity Reduction: 20%. Access and durable remission were top unmet needs.
Regional Difference Insight
Distinct US vs EU hematology KOL perspectives emerged, with EU KOLs placing greater emphasis on reimbursement and patient access, while US KOLs focus more on treatment logistics and referral pathways.
Adoption Barrier Insight
CAR-T adoption barriers remain closely tied to access, referral logistics, treatment cost, reimbursement, and real-world delivery capacity. These challenges will shape how quickly CAR-T therapy insights translate into broader clinical adoption.
Key Executive Insights
Key Findings from the Hematology KOL Perception Study
| Theme | Key Finding |
|---|---|
| CAR-T Therapy | Considered the most impactful advancement by 60% of KOLs, reinforcing the importance of ongoing CAR-T therapy insights despite persistent CAR-T adoption barriers. |
| Bispecific Antibodies | Broadly viewed as a major step forward due to ease of administration and strong efficacy, highlighting growing confidence in bispecific antibodies in hematology. |
| Gene Editing | Strong enthusiasm for gene editing in hematology, with 70% of respondents highly optimistic about future clinical impact. |
| MRD-Guided Care | MRD-guided treatment strategies are expected to become a routine component of treatment decision-making over the next 5 years. |
| Regional Differences | Distinct US vs EU hematology KOL perspectives emerged, with EU KOLs placing greater emphasis on reimbursement and patient access, while US KOLs focus more on treatment logistics and referral pathways. |
| Future Innovation | Multiple myeloma treatment innovations remain an area where KOLs expect the greatest near-term therapeutic advances. |
| Unmet Needs | Improving patient access and achieving more durable remissions continue to be the highest priorities across hematology practice. |
Conclusion
Overall Study Conclusion
Hematology stands at a pivotal moment. This hematology KOL perception study reveals widespread confidence in the transformative potential of CAR-T therapies, bispecific antibodies, gene editing, and MRD-driven care. At the same time, experts emphasize that access, reimbursement, and long-term durability must evolve alongside scientific progress.
For pharmaceutical companies, medical affairs teams, healthcare providers, and investors, these findings offer an important strategic signal: the future of hematology will be defined not simply by innovation itself, but by the ability to deliver that innovation efficiently, equitably, and sustainably.
These future trends in hematology treatment innovations and expert insights demonstrate that organizations aligning breakthrough science with real-world implementation will shape the next generation of hematology care. As a result, this study serves as both a source of hematology market intelligence and a practical guide for stakeholders navigating a rapidly evolving therapeutic landscape.
FAQs
Frequently Asked Questions
What advancement has had the greatest impact on hematology practice?
According to surveyed KOLs, CAR-T therapy was considered the most transformative advancement by 60% of respondents, making it a central theme in current CAR-T therapy insights.
Why are bispecific antibodies gaining popularity?
They offer strong efficacy while reducing manufacturing complexity and improving treatment accessibility, supporting positive sentiment around bispecific antibodies in hematology.
What is the biggest barrier to CAR-T adoption?
Access-related challenges, including referral logistics and reimbursement constraints, remain the primary CAR-T adoption barriers identified by KOLs.
How optimistic are experts about gene editing?
Seventy percent of KOLs reported being very optimistic about the future impact of gene editing in hematology.
Which disease area is expected to see the most innovation?
Multiple myeloma treatment innovations emerged as the leading area for future therapeutic advances.
What is MRD-guided treatment?
MRD-guided treatment strategies use measurable residual disease testing to personalize treatment decisions and monitor disease progression.
Will MRD testing become standard practice?
Most KOLs believe MRD-guided strategies will become routine within the next five years.
What unmet needs remain in hematology?
Achieving durable remissions and improving equitable patient access remain the highest priorities identified in this KOL perception of recent advancements in hematology study.
